M&A Advisory in Maryland
Maryland M&A runs on Fort Meade: GovCon-focused PE fired 125 defense/government deals in Q3 2025 alone (+30% YoY), Arlington Capital closed a $6B Fund VII, and cleared cyber targets around NSA still clear 10x-13x EBITDA despite DOGE's ~5,300-job shock.
Maryland's M&A Economy
Maryland's M&A market is bifurcated and defense-anchored. The GovCon engine drove double-digit deal growth in 2025 — Raymond James tracked 125 defense/government transactions in Q3 2025 alone, up 30% year-over-year, with PE buyers accounting for 45% of deal count. Meanwhile, the broader middle market declined, with GF Data reporting Q3 2025 volume down ~20% sequentially at 7.5x median EV/EBITDA. Arlington Capital Partners closed a $6B Fund VII in October 2025 and launched GRVTY, a new cyber/SIGINT platform at $100M+ revenue. DOGE-driven federal workforce reductions eliminated approximately 5,300 Maryland federal jobs, pressuring uncleared government services firms by 1-2 EBITDA turns while accelerating consolidation among cleared contractors around the Fort Meade/NSA corridor. The post-election DoD pivot toward AI, cyber, and space is the single largest driver of Maryland deal flow going into 2026.
Maryland at a Glance
Key Markets in Maryland
Baltimore MSA
Maryland's largest metropolitan economy anchored by Johns Hopkins Medicine, the University of Maryland Medical System, Port of Baltimore logistics, and a dense advanced manufacturing base. Healthcare M&A is the dominant mid-market vertical, with growing logistics and industrial activity post-bridge reconstruction.
Bethesda/Montgomery County
The #3 U.S. biopharma cluster and primary hub for federal IT and cybersecurity contracting. Home to 350+ life-science firms along the I-270 corridor and dozens of mid-tier GovCon and federal IT integrators serving HHS, NIH, FDA, and NSA-adjacent agencies.
Annapolis
Maryland's capital hosts a professional services and government affairs ecosystem, with growing managed cybersecurity and MSSP activity serving state government and mid-Atlantic commercial clients. Marine industry and hospitality represent secondary M&A verticals.
Frederick
Frederick County anchors biodefense and life sciences activity through USAMRIID and Fort Detrick, alongside a growing advanced manufacturing and construction/specialty trades base. A proposed $1.2B data center campus adds a new emerging vertical.
How Does Maryland Compare?
Maryland M&A benchmarks vs. neighboring states.
Maryland Deal Landscape 2025-2026
Maryland's M&A market is structurally bifurcated. The GovCon and cybersecurity segment is running at multi-year highs — Raymond James tracked 125 defense/government transactions in Q3 2025, up 30% year-over-year, with PE representing 45% of deal count. Arlington Capital's $6B Fund VII close and the GRVTY launch signal continued sponsor appetite for cleared platforms. In contrast, the broader middle market tracked national declines, with GF Data reporting Q3 2025 median EV/EBITDA at 7.5x, down ~20% sequentially. DOGE's elimination of approximately 5,300 Maryland federal jobs has created a two-speed market: cleared GovCon and cyber platforms are accelerating, while uncleared civilian-agency-dependent businesses face 1-2 EBITDA turn discounts and longer sale processes.
DOGE-Driven Flight-to-Cleared Consolidation
Federal workforce reductions under DOGE have bifurcated the GovCon market. Cleared contractors are consolidating — Synergy ECP acquired NetServices, PCS-Mosaic merged with Athenix, SAIC acquired SilverEdge for $205M — while uncleared government services shops face 1-2 EBITDA turn haircuts as civilian agency budgets contract.
Cyber/All-Domain Roll-Ups Centered on Fort Meade
Arlington Capital launched GRVTY and closed its $6B Fund VII; AeroVironment acquired BlueHalo for $4.1B; Parsons acquired CTI for ~$89M; Leidos acquired Kudu Dynamics. The NSA/CYBERCOM/DISA corridor is the most active geographic cluster for sponsor-backed cyber consolidation in the U.S.
I-270 CDMO Consolidation Post-Catalent
Catalent's $16.5B sale to Novo Nordisk triggered cascading CDMO consolidation: Emergent divested Bayview to Syngene ($36.5M) and Camden to Bora ($30M); SK bioscience acquired IDT Biologika ($244M); Jabil acquired Pii; Ascend merged with ABL. The I-270 corridor is being rationalized into larger, therapeutically specialized platforms.
Hopkins/UMMS Digital Health + Data Center Adjacency
Baltimore's healthcare ecosystem is generating digital-health M&A through Hopkins spinouts (Bluesight/Protenus) and data center investment (Sansone $28.8M Silver Spring data center, $1.2B Frederick campus). Digital health SaaS and health IT companies with Hopkins institutional relationships command meaningful valuation premiums.
Exit Preparation Timeline
A practical roadmap for Maryland business owners planning an exit.
- Begin estate freeze planning — GRATs, IDGTs, and SLATs before Maryland's fixed $5M estate tax exemption creates urgency; coordinate with Maryland estate counsel on both estate and inheritance tax exposure.
- Stack QSBS eligibility under IRC §1202 where applicable and confirm Maryland's conformity to federal QSBS exclusion.
- Initiate PET election analysis under Maryland's expanded post-12/31/2025 rules to lock in above-the-line deduction benefit for pass-through owners.
- Begin GovCon contract portfolio assessment — map prime contracts by agency, clearance level, and novation requirement to identify critical path items.
- File Voluntary Disclosure Agreement (VDA) through Maryland Tax Connect for any multi-state nexus exposure and obtain Comptroller clearance strategy.
- Conduct controlling interest analysis under SDAT rules to assess whether a stock sale triggers the controlling interest transfer tax and model vs. asset sale alternatives.
- Commission Quality of Earnings with Maryland-specific normalizations: BRAC-related overhead, cleared facility costs, GSA schedule compliance costs, and BRFA 2025 tax adjustments.
- Initiate DCSA novation pre-notification where possible and confirm FCL/FOCI review posture with cleared facility security officer (FSO).
- Model asset vs. stock structure with full Maryland tax stack: 6% bulk sales tax on asset deals + 2% capital gains surtax + DAGRT + controlling interest transfer tax on stock deals.
- Optimize PET election timing to maximize federal deductibility benefit before the sale.
- Obtain Comptroller of Maryland clearance certificate — allow 30-60 days for processing.
- If applicable, engage MHCC (Maryland Health Care Commission) for Certificate of Ongoing Operations (COO) pre-notification for healthcare transactions subject to CON requirements.
- File Comptroller of Maryland tax clearance certificate (30-60 day lead time required) — closing cannot proceed without it.
- File SDAT Controlling Interest Transfer Report within 30 days of close if applicable.
- File short-period DAGRT (Digital Advertising Gross Revenues Tax) return if seller was a DAGRT filer.
- Structure rollover equity and earnout with Maryland estate and gift tax counsel to address MET-1 (Maryland Estate Tax Return) implications of deferred consideration.
Why Maryland Business Owners Choose Ad Astra
Local market knowledge and national buyer networks — the combination that drives premium outcomes for Maryland business owners.
Schedule a ConsultationGovCon Novation & FOCI Critical Path
FAR novation, facility clearance (FCL) transfer, and Foreign Ownership Control and Influence (FOCI) mitigation are on the critical path of 70%+ of Maryland M&A deals. We manage DCSA novation timelines (6-9 months), FCL/FOCI review (6-18 months), and structure transactions to preserve clearance continuity and avoid constructive termination of classified contracts.
BRFA 2025 Tax Modeling
Maryland's Budget Reconciliation and Financing Act of 2025 created new 6.25%/6.5% income brackets, a permanent 2% capital gains surtax above $350K AGI, and expanding PET elections — producing an effective ~11.8% combined rate on capital gains. We model asset vs. stock scenarios incorporating the 6% bulk sales tax, 2% surtax, DAGRT, and controlling interest transfer tax to identify structure that minimizes total tax leakage.
Estate + Inheritance Tax Planning
Maryland is the only U.S. state imposing BOTH an estate tax (fixed $5M exemption, rates to 16%) AND an inheritance tax (10% on non-lineal heirs). Pre-close estate freezing through GRATs, IDGTs, and SLATs before the $5M exemption locks in, combined with QSBS stacking, can save 3-6% of enterprise value on transactions above $20M.
I-270 Life Sciences & CDMO Sector Network
Our relationships span Montgomery County's 350+ life-science firms, major CDMO buyers (Novo, Syngene, SK bioscience, Jabil, Ascend), and the NIH/FDA-adjacent investor community. We bring strategic and financial buyers to the table who understand CDMO-specific quality systems, FDA compliance posture, and Biologics License Application (BLA) value.
Recent Maryland M&A Activity
SAIC acquired SilverEdge Government Solutions from Godspeed Capital for $205M, adding cleared cyber and intelligence analytics capabilities adjacent to Fort Meade.
Novo Nordisk closed its $16.5B acquisition of Catalent, anchoring over $230M in cumulative Baltimore-Washington corridor capex and 700 local jobs across the I-270 CDMO cluster.
Syngene International acquired Emergent BioSolutions' Bayview facility for $36.5M; Bora Pharmaceuticals acquired Emergent's Camden facility for ~$30M, completing the Emergent divestiture program.
Arlington Capital Partners closed its $6B Fund VII in October 2025 and launched GRVTY, a new cleared cyber/SIGINT platform at $100M+ revenue and 325 staff, headquartered in the Fort Meade corridor.
Bluesight acquired Protenus, a Johns Hopkins spinout specializing in pharmacy diversion analytics and health data intelligence, expanding Bluesight's hospital compliance platform.
Maryland Tax & Deal Structure
Maryland's BRFA 2025 (signed May 20, 2025) fundamentally reset the state's tax burden on business sale proceeds. New top personal income brackets of 6.25%/6.5% plus a permanent 2% capital gains surtax above $350K AGI — layered with a 3.3% county piggyback — produce an effective ~11.8% combined rate on capital gains, among the highest in the Mid-Atlantic. Maryland uniquely imposes BOTH an estate tax (fixed $5M exemption, rates to 16%) AND an inheritance tax (10% on non-lineal heirs). Structure decisions — asset vs. stock, PET election, §453 installment sale, rollover equity — can shift after-tax proceeds by 8-15% of enterprise value, making pre-close tax planning the highest-ROI activity for Maryland sellers.
BRFA 2025 Capital Gains Surtax
UnfavorablePermanent 2% surtax on capital gains above $350K AGI, stacked on new 6.25%/6.5% top income brackets plus 3.3% county piggyback, producing ~11.8% effective combined rate. No sunset provision.
Pass-Through Entity Tax (PET)
FavorableMaryland PET at 8.0%/8.25% expands post-12/31/2025 to additional entity types. PET election allows above-the-line federal deduction for state taxes, partially offsetting SALT cap exposure for pass-through owners.
Dual Estate + Inheritance Tax
UnfavorableMaryland is the only U.S. state imposing both estate tax (fixed $5M exemption, rates to 16%) and inheritance tax (10% on non-lineal heirs). Estate freezing 24+ months pre-close through GRATs/IDGTs/SLATs is critical for deals above $20M.
QSBS Conformity
FavorableMaryland conforms to federal QSBS (IRC §1202) exclusion. Sellers in qualifying C-corps can exclude up to $10M (or 10x basis) of gain from Maryland income tax, subject to five-year holding period and active business requirements.
Controlling Interest Transfer Tax (~1-3%)
NeutralMaryland imposes a transfer tax on controlling interest transfers in entities holding Maryland real property, assessed as a percentage of the property's assessed value. SDAT filing required within 30 days of close. Can make asset sale comparably attractive for real-property-heavy businesses.
Digital Advertising Gross Revenues Tax (DAGRT)
UnfavorableMaryland's DAGRT (2.5-10% graduated by revenue) applies to digital advertising services. Technology and digital services companies with advertising-adjacent revenue streams should model DAGRT exposure and short-period return obligations at close.
Maryland Deal Case Study
Illustrative model only. Not representative of a current or past Ad Astra Equity client engagement. Representative transaction. Details generalized to protect confidentiality.
The Business
Bethesda biotech/specialty pharma services firm providing early-phase CRO and CDMO capabilities to mid-size biopharma clients along the I-270 corridor. 110-160 FTEs with approximately 35% PhD/MS-level staff and 20+ personnel holding active government security clearances supporting NIH-adjacent federal research contracts.
Key Metrics
Revenue
$28M-$42MEBITDA
$6M-$10MEBITDA Margin
~22-25%Enterprise Value
$75M-$115MEV/EBITDA Multiple
11.0-13.0xPremium to Initial Offer
22-30%The Challenge
The seller faced a compressed timeline driven by BRFA 2025 — the permanent 2% capital gains surtax created a material after-tax difference between a 2025 and 2026 close. Simultaneously, 20+ staff held active clearances requiring DCSA novation pre-notification, a FOCI analysis for the international strategic bidder, and coordination with the cognizant contracting officer on three active NIH prime contracts. The COO requirement under MHCC added a parallel regulatory track.
The Process
- 1Initiated DCSA novation pre-notification and FOCI analysis in parallel with QoE — not sequentially — to compress the GovCon regulatory critical path by approximately 4 months.
- 2Structured a dual-track process targeting both domestic financial sponsors (Arlington Capital, Sagewind) and international strategics (European CDMO platforms), using the FOCI track to pre-screen international bidders for clearance-compatible ownership structures.
- 3Ran estate freeze transactions (GRAT + IDGT) for the two founding shareholders 18 months pre-close, removing approximately $22M of enterprise value from the Maryland estate tax base before the $5M fixed exemption became binding.
- 4Modeled asset vs. stock structure with full Maryland tax stack: stock sale with 15-20% rollover equity reduced the seller's effective rate by approximately 2.1 points vs. a clean stock sale, while §453 installment note (~8% face) deferred approximately $4.2M of gain recognition.
- 5Obtained Comptroller tax clearance certificate 45 days pre-close; filed SDAT Controlling Interest Transfer Report at close; structured earnout with MET-1 (Maryland Estate Tax Return) counsel to minimize inheritance tax exposure on deferred consideration.
Deal Outcome
Enterprise Value
$75M-$115M
Premium vs. Market
22-30% above initial offer
Time to Close
10-12 months
Seller Rollover
Stock sale with 15-20% rollover equity, 10-12% escrow (18-month general / 36-month tax), ~10% earnout tied to Phase II/III contract milestones, §453 seller note (~8% face value)
Key Lessons
- Sequencing DCSA novation and FOCI in parallel with QoE — rather than post-LOI — compressed the GovCon regulatory critical path by 4+ months and was the single largest factor enabling a 2025 vs. 2026 close.
- Estate freeze transactions executed 18+ months pre-close generated estimated after-tax value preservation of $3.5M-$6M relative to a no-planning baseline — exceeding total advisory fees.
- BRFA 2025 created a quantifiable urgency: the 2% permanent surtax differential between 2025 and 2026 close represented approximately $1.5M-$2.3M of after-tax proceeds at this transaction size.
- Dual-track process (domestic PE + international strategic) produced a 22-30% premium over the initial PE offer by introducing a therapeutic-fit strategic buyer with a higher synergy-adjusted EBITDA multiple.
Frequently Asked Questions
Common questions about selling a business in Maryland.
Still have questions? Let's talkAlso serving neighboring states
Ready to Explore Your Maryland Exit?
Schedule a confidential conversation to discuss your Maryland business, your goals, and how our local expertise and national buyer network can maximize your outcome.